Jessica Donington, MD, MSCR: There’s one more factor that in 2021 plays a huge role in how we determine upfront treatment and treatment plans altogether and that’s something called molecular testing.

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers. Joshua Sabari, MD: I recommend testing up front. All patients with ...

Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...

As with many things in the healthcare industry, molecular labs are evolving at an incredible pace with advances in everything from instrumentation to service delivery and more. No longer the ...

IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...

Antimicrobial resistance (AMR) remains a major global healthcare challenge, undermining the effectiveness of treatments for common infections and threatening modern medical advances. Improved ...

ROCKVILLE, Md. – March 31, 2025 – The Association for Molecular Pathology, the premier global molecular diagnostic professional society, and pathologist Michael Laposata , M.D. , Ph.D., today ...

Please provide your email address to receive an email when new articles are posted on . During the past 2 decades, Endocrine Today has reported on the latest developments in treating thyroid cancer.

3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...